Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
News|Articles|June 1, 2002
Benicar (Olmesartan medoxomil) Sankyo Pharma/Forest Laboratories
NME: 7th ARB approved for hypertension
Advertisement
Advertisement
Related to this article
The trade group argues CMS exceeded its authority with GLOBE, a Medicare Part B model tying drug rebates to prices in 19 other countries.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Melanoma care is shifting to risk-based screening and treatment before surgery | Fall Clinical Derm 2026
2
Why biosimilars keep losing ground to brand-name rivals: A Q&A with Christine Johnston, MBA
3
Chronic hand eczema needs more than topical steroids | Fall Clinical Derm 2026
4
Choosing a first biologic for HS, as recommended by Jennifer Hsiao, M.D. | Fall Clinical Derm 2026
5